Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors

Leukemia

Volumn 31, Issue 2, 2017, Pages 479-490

  Donato, E ^a   Croci, O ^a   Sabo A ^a   Muller, H ^a   Morelli, M J ^a   Pelizzola, M ^a   Campaner, S ^a  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; BROMODOMAIN AND EXTRATERMINAL PROTEIN; MESSENGER RNA; MYC PROTEIN; PROTEIN; RNA POLYMERASE II; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; BRD4 PROTEIN, HUMAN; CHROMATIN; CYCLIN DEPENDENT KINASE 9; NUCLEAR PROTEIN; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER CELL; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL FUNCTION; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DNA REPLICATION; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; EMBRYO; FIBROBLAST; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MACHINE LEARNING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAJI CELL LINE; TRANSCRIPTION ELONGATION; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; ENHANCER REGION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; TUMOR CELL LINE;

AZEPINES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN; CYCLIN-DEPENDENT KINASE 9; E2F TRANSCRIPTION FACTORS; ENHANCER ELEMENTS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MYC; RNA POLYMERASE II; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRIAZOLES;

EID: 84979300705     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.182     Document Type: Article

References (63)

1. Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, metabolism, and cancer. Cancer Discov 2015; 5: 1024-1039.
2. Kress TR, Sabo A, Amati B. MYC: connecting selective transcriptional control to global RNA production. Nat Rev Cancer 2015; 15: 593-607.
3. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982; 79: 7824-7827.
4. Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA 1982; 79: 7837-7841.
5. Crews S, Barth R, Hood L, Prehn J, Calame K. Mouse c-myc oncogene is located on chromosome 15 and translocated to chromosome 12 in plasmacytomas. Science 1982; 218: 1319-1321.
6. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008; 8: 976-990.
7. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004; 431: 1112-1117.
8. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002; 297: 102-104.
9. Soucek L, Whitfield JR, Sodir NM, Masso-Valles D, Serrano E, Karnezis AN et al. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev 2013; 27: 504-513.
10. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 2002; 109: 321-334.
11. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 2011; 108: 16669-16674.
12. Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 2012; 149: 214-231.
13. Rahman S, Sowa ME, Ottinger M, Smith JA, Shi Y, Harper JW et al. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol Cell Biol 2011; 31: 2641-2652.
14. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O et al. Selective inhibition of BET bromodomains. Nature 2010; 468: 1067-1073.
15. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011; 478: 529-533.
16. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: 524-528.
17. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-917.
18. Murga M, Campaner S, Lopez-Contreras AJ, Toledo LI, Soria R, Montana MF et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol 2011; 18: 1331-1335.
19. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA et al. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 2008; 14: 447-457.
20. Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, Sardella D et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol 2010; 12: 54-59.
21. Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M et al. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep 2013; 5: 1704-1713.
22. Liu L, Xu Y, He M, Zhang M, Cui F, Lu L et al. Transcriptional pause release is a rate-limiting step for somatic cell reprogramming. Cell Stem Cell 2014; 15: 574-588.
23. Sabo A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature 2014; 511: 488-492.
24. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
25. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol 2008; 9: R137.
26. Kishore K, de Pretis S, Lister R, Morelli MJ, Bianchi V, Amati B et al. methylPipe and compEpiTools: a suite of R packages for the integrative analysis of epigenomics data. BMC Bioinformatics 2015; 16: 313.
27. Liaw A, Wiener M. Classification and regression by random forest. R News 2002; 3: 18-22.
28. Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013; 153: 320-334.
29. Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB et al. c-Myc regulates transcriptional pause release. Cell 2010; 141: 432-445.
30. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318: 533-538.
31. Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov 2013; 3: 308-323.
32. Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012; 120: 2843-2852.
33. Althoff K, Beckers A, Bell E, Nortmeyer M, Thor T, Sprussel A et al. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. Oncogene 2015; 34: 3357-3368.
34. Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 2013; 24: 777-790.
35. Bhadury J, Nilsson LM, Muralidharan SV, Green LC, Li Z, Gesner EM et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci USA 2014; 111: E2721-E2730.
36. Seitz V, Butzhammer P, Hirsch B, Hecht J, Gutgemann I, Ehlers A et al. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma. PLoS One 2011; 6: e26837.
37. Anders L, Guenther MG, Qi J, Fan ZP, Marineau JJ, Rahl PB et al. Genome-wide localization of small molecules. Nat Biotechnol 2014; 32: 92-96.
38. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andre V, Sigova AA et al. Superenhancers in the control of cell identity and disease. Cell 2013; 155: 934-947.
39. Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell 2014; 159: 1126-1139.
40. Pelish HE, Liau BB, Nitulescu II, Tangpeerachaikul A, Poss ZC, Da Silva DH et al. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature 2015; 526: 273-276.
41. Zippo A, Serafini R, Rocchigiani M, Pennacchini S, Krepelova A, Oliviero S. Histone crosstalk between H3S10ph and H4K16ac generates a histone code that mediates transcription elongation. Cell 2009; 138: 1122-1136.
42. Kanno T, Kanno Y, LeRoy G, Campos E, Sun HW, Brooks SR et al. BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. Nat Struct Mol Biol 2014; 21: 1047-1057.
43. Yang Z, Yik JH, Chen R, He N, Jang MK, Ozato K et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell 2005; 19: 535-545.
44. Liu W, Ma Q, Wong K, Li W, Ohgi K, Zhang J et al. Brd4 and JMJD6-associated antipause enhancers in regulation of transcriptional pause release. Cell 2013; 155: 1581-1595.
45. Kellner WA, Van Bortle K, Li L, Ramos E, Takenaka N, Corces VG. Distinct isoforms of the Drosophila Brd4 homologue are present at enhancers, promoters and insulator sites. Nucleic Acids Res 2013; 41: 9274-9283.
46. Zhang W, Prakash C, Sum C, Gong Y, Li Y, Kwok JJ et al. Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem 2012; 287: 43137-43155.
47. Zippo A, De Robertis A, Serafini R, Oliviero S. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol 2007; 9: 932-944.
48. Benayoun BA, Pollina EA, Ucar D, Mahmoudi S, Karra K, Wong ED et al. H3K4me3 breadth is linked to cell identity and transcriptional consistency. Cell 2014; 158: 673-688.
49. Guccione E, Martinato F, Finocchiaro G, Luzi L, Tizzoni L, Dall' Olio V et al. Myc-binding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol 2006; 8: 764-770.
50. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012; 151: 56-67.
51. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012; 151: 68-79.
52. Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell 2005; 19: 523-534.
53. Hargreaves DC, Horng T, Medzhitov R. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 2009; 138: 129-145.
54. Kanazawa S, Soucek L, Evan G, Okamoto T, Peterlin BM. c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis. Oncogene 2003; 22: 5707-5711.
55. Eberhardy SR, Farnham PJ. c-Myc mediates activation of the cad promoter via a post-RNA polymerase II recruitment mechanism. J Biol Chem 2001; 276: 48562-48571.
56. Eberhardy SR, Farnham PJ. Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter. J Biol Chem 2002; 277: 40156-40162.
57. Gargano B, Amente S, Majello B, Lania L. P-TEFb is a crucial co-factor for Myc transactivation. Cell Cycle 2007; 6: 2031-2037.
58. Baranello L, Wojtowicz D, Cui K, Devaiah BN, Chung HJ, Chan-Salis KY et al. RNA polymerase II regulates topoisomerase 1 activity to favor efficient transcription. Cell 2016; 165: 357-371.
59. Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ et al. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev 2014; 28: 1800-1814.
60. Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci USA 2012; 109: 9545-9550.
61. Gilchrist DA, Fromm G, dos Santos G, Pham LN, McDaniel IE, Burkholder A et al. Regulating the regulators: the pervasive effects of Pol II pausing on stimulusresponsive gene networks. Genes Dev 2012; 26: 933-944.
62. Williams LH, Fromm G, Gokey NG, Henriques T, Muse GW, Burkholder A et al. Pausing of RNA polymerase II regulates mammalian developmental potential through control of signaling networks. Mol Cell 2015; 58: 311-322.
63. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J et al. Global quantification of mammalian gene expression control. Nature 2011; 473: 337-342.